Enzo Biochem Stock Story

ENZ
 Stock
  

USD 2.59  0.08  3.00%   

Agilent Technologies would recover faster from the current slip as its shares price went up 0.33% to Enzo Biochem's 1.23%As many investors are getting excited about healthcare space, Enzo Biochem and Agilent Technologies may be going in opposite directions. We are going to inspect some of the competitive aspects of both Enzo Biochem and Agilent.
Published over two months ago
View all stories for Enzo Biochem | View All Stories

Will Agilent Technologies investors switch to Enzo Biochem (NYSE:ENZ)?

By analyzing existing basic indicators between Enzo Biochem and Agilent, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Agilent with a short position in Enzo Biochem. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Enzo Biochem has an asset utilization ratio of 105.68 percent. This suggests that the company is making $1.06 for each dollar of assets. An increasing asset utilization means that Enzo Biochem is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as Enzo Biochem or Agilent is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Enzo Biochem's Liquidity

Enzo Biochem financial leverage refers to using borrowed capital as a funding source to finance Enzo Biochem ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Enzo Biochem financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Enzo Biochem's total debt and its cash.

Correlation Between Enzo Biochem and Agilent Technologies

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Enzo Biochem together with similar or unrelated positions with a negative correlation. For example, you can also add Agilent Technologies to your portfolio. If Agilent Technologies is not perfectly correlated to Enzo Biochem it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Enzo Biochem for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Please check pair correlation details between ENZ and A for more information.

Note

Are you currently holding both Enzo Biochem and Agilent Technologies in your portfolio?
Please note if you are using this as a pair-trade strategy between Enzo Biochem and Agilent Technologies, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses.

Enzo Biochem exotic insider transaction detected

Legal trades by Enzo Biochem insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Enzo Biochem insider trading alert for general transaction of common stock $0.01 par value by Kara Cannon, Chief Operating Officer, on 19th of July 2022. This event was filed by Enzo Biochem Inc with SEC on 2022-07-19. Statement of changes in beneficial ownership - SEC Form 4. Kara Cannon currently serves as corporate vice president - commercial operations of Enzo Biochem [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Lets now take a look at Enzo Biochem revenue. Based on the latest financial disclosure, Enzo Biochem reported 118.17 M of revenue. This is 98.45% lower than that of the Healthcare sector and 94.04% lower than that of the Diagnostics & Research industry. The revenue for all United States stocks is 98.75% higher than that of Enzo Biochem. As for Agilent Technologies we see revenue of 6.45 B, which is 225.5% higher than that of the Diagnostics & Research

Sector
B
A
6.5 B
ENZ118.17 Million1.38
Sector1.98 Billion23.18
A6.45 Billion75.44

How will Enzo Biochem investors react to the next slide?

Current risk adjusted performance is at -0.25. Enzo Biochem exhibits very low volatility with skewness of -0.23 and kurtosis of 0.09. However, we advise investors to further study Enzo Biochem technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Enzo Biochem's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Enzo Biochem's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Enzo Biochem Implied Volatility

Enzo Biochem's implied volatility exposes the market's sentiment of Enzo Biochem stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Enzo Biochem's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Enzo Biochem stock will not fluctuate a lot when Enzo Biochem's options are near their expiration.

Our Final Perspective on Enzo Biochem

While some firms in the diagnostics & research industry are either recovering or due for a correction, Enzo Biochem may not be performing as strong as the other in terms of long-term growth potentials. To summarize, as of the 9th of June 2022, we believe that at this point, Enzo Biochem is slightly risky with below average probability of financial unrest within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. Our primary 90 days recommendation on the company is Cautious Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Enzo Biochem. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com